A Phase 1 interventional study of AZD9550 solution for injection and AZD6234 solution for injection in Healthy Participants, sponsored by AstraZeneca. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing AZD6234 in Obesity — 2 open to participants now, 4 under way, 1 of them phase 3. AZD6234 · Obesity.
Among the 10 studies testing AZD6234 in Obesity, this one is the 7th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 1, and was the 10th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →2 of the 10 studies testing AZD6234 in Obesity are open now, in 3 countries. Recruiting first, the newest first:
AstraZeneca · Sites in China, India
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 60 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 85 across the 10 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
52 studies in Obesity by AstraZeneca: 8 open now, 12 under way, 5 of them phase 3. Of 40 finished, 9 (23%) have results posted.
Among the 52 studies in Obesity by AstraZeneca, this one is the 29th largest by planned enrollment of the 50 interventional ones that give a count, is one of 9 that started in 2026, is one of 24 in phase 1, reaches primary completion later than 5 of the 11 other live ones, and was the 52nd registered.
AstraZeneca’s Obesity studies by the year they started, since 2004.
2 of the studies testing AZD6234 in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07911514AstraZenecaA Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 | 2027-05-04 |
| NCT07013643AstraZenecaA Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity | 2027-07-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing AZD6234 in Obesity, from their registry updates:
Among AstraZeneca’s 52 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
This study will take place at one site in Nottingham, United Kingdom.
It plans to randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.
Each volunteer will receive a single dose of test medicine by injection under the skin into the abdomen (tummy), either as 2 separate injections (one of each test medicine) or as a single injection where the test medicines are combined. They'll stay in the clinic for 6 nights on 1 occasion, attend up to 5 outpatient visits, and take up to 9 weeks to finish the study.
Blood and urine samples will be collected to measure the amounts of AZD6234 and AZD9550 and a component of the test medicine, do safety tests, and assess the effect of the test medicine on the immune system.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single concomitant SC injections of AZD9550 solution for injection and AZD6234 solution for injection
Drug: AZD9550 solution for injection · Drug: AZD6234 solution for injection
Participants will receive a single SC injection of Formulation 1 solution for injection
Drug: Formulation 1 solution for injection
Participants will receive a single SC injection of Formulation 2 solution for injection
Drug: Formulation 2 solution for injection
Participants will receive a single SC injection of Formulation 3 solution for injection
Drug: Formulation 3 solution for injection
Participants will receive a single SC injection of Formulation 4 solution for injection
Drug: Formulation 4 solution for injection
AZD9550 solution for injection will be administered as a single SC injection
Also known as: AZD9550
AZD6234 solution for injection will be administered as a single SC injection
Also known as: AZD6234
Formulation 1 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Formulation 2 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Formulation 3 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Formulation 4 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Maximum observed plasma concentration (Cmax)
Assess the relative bioavailability (rBA) and compare single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Area under the curve from time 0 to the time of last quantifiable concentration (AUClast)
Assess the relative bioavailability (rBA) and compare the single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Area under the curve from time 0 extrapolated to infinity (AUCinf)
Assess the relative bioavailability (rBA) and compare the single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Number of participants with adverse events (AEs)/serious AEs (SAEs), and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests
Safety and tolerability of single concomitant doses and different fixed-dose coformulations of AZD9550 and AZD6234 following a single subcutaneous (SC) dose
Time frame: Through study duration, approximately 9 weeks
Time of maximum observed concentration (tmax)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Time of last measurable observed concentration (tlast)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformuations
Time frame: Plasma sample collection from pre dose to Day 22
Time prior to the first measurable concentration (tlag)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Terminal elimination half-life (t1/2λz)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Apparent total body clearance (CL/F)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Apparent volume of distribution based on the terminal phase (Vz/F)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Mean residence time from time 0 extrapolated to infinity (MRTinf)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
First order rate constant associated with the terminal (log-linear) portion of the curve (λz)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 5 months later.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 5 months is below that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AZD9550 · AZD6234